Molecular pathways in bladder cancer

Urological Research

Volumn 32, Issue 6, 2004, Pages 373-385

  Williams, Stephen G ^a   Stein, John P ^b  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bladder cancer; Genetic events; Molecular pathway; Transitional cell carcinoma; Tumorigenesis

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; INTERLEUKIN 12; INTERLEUKIN 8; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; SCATTER FACTOR; THALIDOMIDE; THROMBOSPONDIN 1; THYMIDINE PHOSPHORYLASE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; DNA SEQUENCE; EXTRACELLULAR MATRIX; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; METASTASIS; NONHUMAN; ONCOGENE C ERB; ONCOGENE C MYC; ONCOGENE H RAS; PHENOTYPE; PLOIDY; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

CARCINOMA, TRANSITIONAL CELL; CELL CYCLE; CHROMOSOME ABERRATIONS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; URINARY BLADDER NEOPLASMS;

EID: 12344313091     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00240-003-0345-y     Document Type: Review

References (126)

1. Cancer Statistics (2003)
2. Skinner DG, Lieskovsky G (1998) 16 years experience in the management of patients with deeply invasive bladder cancer. Eur Urol 14: 30
3. Droller MJ (1998) Markers in bladder cancer - issues to consider. JUrol 160: 2009
4. Malkowicz SB (1997) Superficial bladder cancer: the role of molecular markers in the treatment of high-risk superficial disease. Semin Urol Oncol 15: 169
5. Adshead JM, Kessling AM, Ogden CW (1998) Genetic initiation, progression and prognostic markers in transitional cell carcinoma of the bladder: a summary of the structural and transcriptional changes, and the role of developmental genes. Br JUrol 82: 503
6. Kroft SH, Oyasu R (1994) Urinary bladder cancer: mechanisms of development and progression. Lab Invest 71: 158
7. Moriyama N, Umeda T, Akaza H et al. (1989) Expression of ras p21 oncogene product on human bladder tumors. Urol Int 44: 260
8. Nagata Y, Abe M, Kobayashi K et al. (1990) Point mutations of c-ras genes in human bladder cancer and kidney cancer. Jpn J Cancer Res 81: 22
9. Fradet Y (1992) Markers of prognosis in superficial bladder cancer. Semin Urol 10: 28
10. Fontana D, Bellina M, Scoffone C et al. (1996) Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur Urol 29: 470
11. Koskinen PJ, Alitalo K (1993) Role of myc amplification and overexpression in cell growth, differentiation and death. Semin Cancer Biol 4: 3
12. Berns EM, Klijn JG, Van Putten WL et al. (1992) c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 52: 1107
13. Kotake T, Saiki S, Kinouchi T et al: (1990) Detection of the c-myc gene product in urinary bladder cancer. Jpn J Cancer Res 81: 1198
14. Watt RA, Shatzman AR, Rosenberg M (1985) Expression and characterization of the human c-myc DNA-binding protein. Mol Cell Biol 5: 448
15. Lipponen PK (1995) Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J Pathol 175: 203
16. Underwood M, Bartlett J, Reeves J et al. (1995) C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 55: 2422
17. Akiyama T, Sudo C, Ogawara H et al. (1986) The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232: 1644
18. Lee J, Dull TJ, Lax I. et al (1989) HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. EMBO J 8: 167
19. Slamon DJ, Godolphin W, Jones LA et al. (1989) Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707
20. Gorgoulis VG, Barbatis C, Poulias I et al. (1995) Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients. Mod Pathol 8: 758
21. Sato K, Moriyama M, Mori S et al. (1992) An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 70: 2493
22. Moriyama M, Akiyama T, Yamamoto T et al (1991) Expression of c-erbB-2 gene product in urinary bladder cancer. J Urol 145: 423
23. Lipponen P, Eskelinen M (1994) Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein(c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 69: 1120
24. Mellon JK, Lunec J, Wright C et al. (1996) C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value [see comments]. J Urol 155: 321
25. Li M, Zhang ZF, Reuter VE et al. (1996) Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. Am J Pathol 149: 229
26. Takle LA, Knowles MA (1996) Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer. Oncogene 12: 1083
27. Wagner U, Bubendorf L, Gasser TC et al. (1997) Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am J Pathol 151: 753
28. Habuchi T, Devlin J, Elder PA et al. (1995) Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene 11: 1671
29. Keen AJ, Knowles MA. (1994) Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 9: 2083
30. Simoneau AR, Spruck CH3rd, Gonzalez-Zulueta M et al. (1996) Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS 1 and PTC mutations. Cancer Res 56: 5039
31. Knowles MA (1999) The genetics of transitional cell carcinoma: progress and potential clinical application. BJU Int 84: 412
32. Orlow I, Lacombe L, Hannon GJ et al. (1995) Deletion of the p16 and p15 genes in human bladder tumors [see comments]. J Nat Cancer Inst 87: 1524
33. Packenham JP, Taylor JA, Anna CH et al. (1995) Homozygous deletions but no sequence mutations in coding regions of p 15 or p16 in human primary bladder tumors. Mol Carcinogen 14: 147
34. Williamson MP, Elder PA, Shaw ME et al. (1995) p16(CDKN2) is a major deletion target at 9p21 in bladder cancer. Human Mol Genet 4: 1569
35. Wu Q, Possati L, Montesi M et al. (1996) Growth arrest and suppression of tumorigenicity of bladder-carcinoma cell lines induced by the P16/CDKN2(p161NK4A, MTS1) gene and other loci on human chromosome 9. Int J Cancer 65: 840
36. Habuchi T, Luscombe M, Elder PA et al. (1988) Structure and methylation-based silencing of a gene(DBCCRI) within a candidate bladder cancer tumor suppressor region at 9932-q33. Genomics 48: 277
37. Habuchi T, Ogawa O, Kakehi Y et al. (1993) Accumulated allelic losses in the development of invasive urothelial cancer. Int J Cancer 53: 579
38. Olumi AF, Tsai YC, Nichols PW et al. (1990) Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 50: 7081
39. Sidransky D, Von Eschenbach A, Tsai YC et al. (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science 252: 706
40. Williamson MP, Elder PA, Knowles MA (1994) The spectrum of TP53 mutations in bladder carcinoma. Genes, Chromosomes Cancer 9: 108
41. Cordon-Cardo C, Dalbagni G, Saez GT et al. (1994) p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 56: 347
42. Esrig D, Spruck CH, Nichols PW et al. (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143: 1389
43. Mareel MM, Van Roy FM, Bracke ME (1993) How and when do tumor cells metastasize? Crit Rev Oncogen 4: 559
44. Sparkes RS, Sparkes MC, Wilson MG et al. (1980) Regional assignment of genes for human esterase D and retinoblastoma to chromosome band 13814. Science 208: 1042
45. Logothetis CJ, Xu HJ, Ro JY et al. (1992) Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer [see comments]. J Nat Cancer Inst 84: 1256
46. Cordon-Cardo C, Wartinger D, Petrylak D et al. (1992) Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer [see comments]. J Nat Cancer Inst 84: 1251
47. Xu HJ, Cairns P, Hu SX et al. (1993) Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer 53: 781
48. Markl ID, Salem CE, Jones PA (2000) Molecular biology of bladder cancer. In: Vogelzang N, Scardino PT, Shipley WU, Coffey DS (eds) Comprehensive textbook of genitourinary oncology (). Lippincott Williams and Wilkins, Philadelphia, p 298
49. Markl ID, Jones PA (1998) Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res 58: 5348
50. Spruck CH3rd, Ohneseit PF, Gonzalez-Zulueta M, et al. (1994) Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54: 784
51. Cordon-Cardo C (1995) Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147: 545
52. Fung YK, Murphree AL, T'Ang A et al. (1987) Structural evidence for the authenticity of the human retinoblastoma gene. Science 236: 1657
53. Presti JCJr., Reuter VE, Galan T et al. (1991) Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 51: 5405
54. Cote RJ, Chatterjee SJ (1999) Molecular determinants of outcome in bladder cancer. Cancer J Sci Am 5: 2
55. Ishikawa J, Xu HJ, Hu SX et al. (1991) Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res 51: 5736
56. Hollstein M, Sidransky D, Vogelstein B et al. (1991) p53 mutations in human cancers. Science 253: 49
57. Lane DP (1992) Cancer. p53, guardian of the genome [see comments]. Nature 358: 15
58. Vet JA, Bringuier PP, Schaafsma HE et al. (1995) Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. Lab Invest 73: 837
59. Dalbagni G, Cordon-Cardo C, Reuter V et al. (1995) Tumor suppressor gene alterations in bladder carcinoma. Translational correlates to clinical practice. Surg Oncol Clinics North Am 4: 231
60. Esrig D, Elmajian D, Groshen S et al. (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer [see comments]. N Engl J Med 331: 1259
61. Sarkis AS, Dalbagni G, Cordon-Cardo C et al (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Nat Cancer Inst 85: 53
62. Greenblatt MS, Bennett WP, Hollstein M et al. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855
63. Cote RJ, Dunn MD, Chatterjee SJ et al. (1998) Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 58: 1090
64. Cordon-Cardo C, Zhang ZF, Dalbagni G et al. (1997) Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57: 1217
65. Parker SB, Eichele G, Zhang P et al. (1995) p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells [see comments]. Science 267: 1024
66. Stein JP, Ginsberg DA, Grossfeld GD et al. (1998) Effect of p21WAF1/CIP1 expression an tumor progression in bladder cancer [see comments]. J Nat Cancer Inst 90: 1072
67. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 [see comments]. Nature 366: 704
68. Gonzalez-Zulueta M, Bender CM, Yang AS et al. (1995) Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55: 4531
69. Chin L, Pomerantz J, DePinho RA (1998) The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochemic Sci 23: 291
70. Quelle DE, Zindy F, Ashmun RA et al. (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993
71. Orlow I, LaRue H, Osman I et al. (1999) Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol 155: 105
72. Pomerantz J, Schreiber-Agus N, Liegeois NJ et al. (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713
73. Momand J, Wu HH, Dasgupta G (2000) MDM2 - master regulator of the p53 tumor suppressor protein. Gene 242: 15
74. Lianes P, Orlow I, Zhang ZF et al. (1994) Altered patterns of MDM2 and TP53 expression in human bladder cancer [see comments]. J Nat Cancer Inst 86: 1325
75. Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43: 175
76. Folkman J (1992) The role of angiogenesis in tumor growth. Semin Cancer Biol 3: 65
77. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353
78. Volpert OV, Dameron KM, Bouck N (1997) Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 14: 1495
79. Polverini PJ (1995) The pathophysiology of angiogenesis. Crit Rev Oral Biol Med 6: 230
80. Blood CH, Zetter BR (1990) Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1032: 89
81. Folkman J (1987) What is the role of angiogenesis in metastasis from cutaneous melanoma? Eur J Cancer Clin Oncol 23: 361
82. Weidner N, Folkman J, Pozza F et al. (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma [see comments]. J Nat Cancer Inst 84: 1875
83. Weidner N, Carroll PR, Flax J et al. (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401
84. Barnhill RL, Piepkorn MW, Cochran AJ et al. (1998) Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases [see comments]. Arch Dermatol 134: 991
85. Bochner BH, Cote RJ, Weidner N et al. (1995) Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Nat Cancer Inst 87: 1603
86. Jaeger TM, Weidner N, Chew K et al. (1995) Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 154: 69
87. Dickinson AJ, Fox SB, Persad RA et al. (1994) Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 74: 762
88. Campbell SC, Volpert OV, Ivanovich M et al (1998) Molecular mediators of angiogenesis in bladder cancer. Cancer Res 58: 1298
89. Chodak GW, Scheiner CJ, Zetter BR (1981) Urine from patients with transitional-cell carcinoma stimulates migration of capillary endothelial cells. N Engl J Med 305: 869
90. Nguyen M, Watanabe H, Budson AE et al (1993) Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Nat Cancer Inst 85: 241
91. O''Brien TS, Harris AL (1995) Angiogenesis in urological malignancy. Br J Urol 76: 675
92. Bochner B, McHugh R, Spitz A, Groshen S, Skinner DG, Nichols PW (1997) Basic fibroblast growth factor (bFGF) in bladder cancer: elevated urinary levels predict pathologic stage. J Urol 157: 341
93. Crew JP, O''Brien T, Bicknell R et al (1999) Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates [see comments]. J Urol 161: 799
94. Williams SG, Feng A, Skinner DG, Nichols PW, Bochner BH (2000) Urine levels of vascular endothelial growth factor predict recurrence in bladder cancer. J Urol 163: 133
95. O''Brien T, Cranston D, Fuggle S et al. (1995) Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 55: 510
96. Sato K, Sasaki R, Ogura Y et al. (1998) Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer. Tohoku J Exp Med 185: 173
97. O'Brien T, Cranston D, Fuggle S et al. (1997) Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. Cancer Res 57: 136
98. D'Amato RJ, Loughnan MS, Flynn E et al. (1994) Thalidomide is an inhibitor of angiogenesis. Proc Nat Acad Sci U.S.A 91: 4082
99. Voest EE, Kenyon BM, O''Reilly MS et al. (1995) Inhibition of angiogenesis in vivo by interleukin 12 [see comments]. J Nat Cancer Inst 87: 581
100. O''Reilly MS, Holmgren L, Shing Y et al. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell 79: 315
101. Sheibani N, Frazier WA (1998) Down-regulation of platelet endothelial cell adhesion molecule-1 results in thrombospondin-1 expression and concerted regulation of endothelial cell phenotype. Mol Biol Cell 9: 701
102. Bochner B, Windham CQ, Pao MM, Kasahara N, Skinner DG, Jones PA (1998) Overexpression of thrombospondin-1 inhibits bladder tumor growth: a novel therapy for invasive bladder cancer. J Urol 159: 282
103. Saito T, Kimura M, Kawasaki T et al. (1996) Correlation between integrin alpha 5 expression and the malignant phenotype of transitional cell carcinoma. Br J Cancer 73:
104. O'Reilly MS, Holmgren L, Chen C et al. (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2: 689
105. Iruela-Arispe ML, Bornstein P, Sage H (1991) Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Nat Acad Sci U.S.A. 88: 5026
106. Good DJ, Polverini PJ, Rastinejad F et al. (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Nat Acad Sci U.S.A 87: 6624
107. Grossfeld GD, Shi SR, Ginsberg DA et al. (1996) Immunohistochemical detection of thrombospondin-1 in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem 44: 761
108. Grossfeld GD, Ginsberg DA, Stein JP et al (1997) Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Nat Cancer Inst 89: 219
109. Joseph A, Weiss GH, Jin L et al. (1995) Expression of scatter factor in human bladder carcinoma. J Nat Cancer Inst 87: 372
110. Gohji K, Fujimoto N, Fujii A et al. (1996) Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res 56: 3196
111. Gohji K, Fujimoto N, Ohkawa J et al. (1998) Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer 77: 650
112. Folkman J (1995) Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis [see comments]. N Engl J Med 333: 1757
113. Boehm T, Folkman J, Browder T et al. (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [see comments]. Nature 390: 404
114. Folkman J (1997) Angiogenesis and angiogenesis inhibition: an overview. Exs 79: 1
115. Schlaeppi JM, Wood JM (1999) Targeting vascular endothelial growth factor(VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev 18: 473
116. Siemeister G, Martiny-Baron G, Marme D (1998) The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Cancer Metastasis Rev 17: 241
117. Bichler KH, Wechsel HW (1999) The problematic nature of metastasized renal cell carcinoma. Anticancer Res 19: 1463
118. Campbell SC, Bochner BH (1998) Angiogenesis in bladder cancer. Mol Urol 2: 279
119. Chopin DK, Caruelle JP, Colombel M et al. (1993) Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol 150: 1126
120. Ravery V, Jouanneau J, Gil Diez S, et al. (1992) Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma. Urol Res 20: 211
121. Crew JP, O'Brien T, Bradburn M et al. (1997) Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 57: 5281
122. O'Brien TS, Fox SB, Dickinson AJ et al. (1996) Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res 56: 4799
123. Rosen EM, Goldberg ID (1997) Regulation of angiogenesis by scatter factor. Exs 79: 193
124. Eder IE, Stenzl A, Hobisch A et al. (1996) Transforming growth factors-beta 1 and Beta 2 in serum and urine from patients with bladder carcinoma [see comments]. J Urol 156: 953
125. Andrawis R, Contrino J, Lindquist RR et al. (1997) Interleukin-8 expression and human bladder cancer:in-situ and in-vitro expression of IL-8 by human bladder cancer cells. J Urol 157: 28
126. Gohji K, Fujimoto N, Komiyama T et al. (1996) Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 78: 2379